Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

CONCLUSIONSAvelumab generally was found to be well tolerated and to have a manageable safety profile. A minority of patients experienced grade ≥3 TRAEs or irAEs, and discontinuation was uncommon. IRRs occurred mainly at the time of first infusion, and repeated events were infrequent. Cancer 2018. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Source: Cancer - February 22, 2018 Category: Cancer & Oncology Authors: Karen Kelly, Jeffrey R. Infante, Matthew H. Taylor, Manish R. Patel, Deborah J. Wong, Nicholas Iannotti, Janice M. Mehnert, Anja H. Loos, Helga Koch, Isabell Speit, James L. Gulley Tags: Original Article Source Type: research